Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in metastatic pancreatic ductal adenocarcinoma
NCT02981342Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Disease Control Rate at 6 months and Progression Free Survival at 6 months. Started Jan 2017; status: completed.
02
Drugs
abemaciclib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02981342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981342.